Phase I clinical studies of S-1090: Safety and pharmacokinetics

Journal of Infection and Chemotherapy

Volumn 2, Issue 4, 1996, Pages 271-279

  Nakashima, Mitsuyoshi ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Oral cephem antibiotic; Pharmacokinetics; Phase I clinical studies; S 1090

Indexed keywords

EID: 0344264734     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02355128     Document Type: Article

References (19)

1. Kume M, Kubota T, Kimura Y, Nakashimizu H, Motokawa K. Orally active cephalosporins. IV. Synthesis, antibacterial activity and oral absorption of 3-(1H-1,2,3-triazol-4-yl) thiomethylthiocephalosporins. Chem Pharm Bull 1993;41:758-762.
2. Murakami K, Kubota T, Sasaki S, Miwa H, Kimura Y, Komatsu Y, et al. S-1090, a new oral cephalosporin I. Antibacterial activity. 32nd Intersci Conf Antimicrob Agents Chemother 1992 (abstr 183).
3. Tsuji M, Ishii Y, Ohno A, Miyazaki S, Yamaguchi K. In vitro antibacterial activity of 8-1090, a new oral cephalosporin I. 35th Intersci Conf Antimicrob Agents Chemother 1995 (abstr 107).
4. Sasaki S, Kimura Y, Shimada J, Kuwahara S. In vitro antibacterial activity of S-1090, a new oral cephalosporin, against various bacteria including H. influenzae. 35th Intersci Conf Antimicrob Agents Chemother 1995 (abstr 109).
5. Kimura Y, Nakashimizu H, Murakami K, Koike M, Nishiuchi M, Kuwahara S. S-1090, a new oral cephalosporin II. Pharmacokinetics in animals. 32nd Intersci Conf Antimicrob Agents Chemother 1992 (abstr 184).
6. Nishino T, Otsuki M, Inoue R. In vitro and in vivo antibacterial activity of S-1090, a new oral cephalosporin. 35th Intersci Conf Antimicrob Agents Chemother 1995 (abstr 111).
7. Miyazaki S, Tsuji M, Ishii Y, Ohno A, Yamaguchi K. In vivo antibacterial activity of S-1090, a new oral cephalosporin II. 35th Intersci Conf Antimicrob Agents Chemother 1995 (abstr 113).
8. Tsuji M, Ishii Y, Ohno A, Miyazaki S, Yamaguchi K. In vitro and in vivo antibacterial activities of S-1090, a new oral cephalosporin. Antimicrob Agents Chemother 1995;39:2544-2551.
9. Kimura Y, Nakano M, Yoshida T. Microbiological assay methods for 6315-S (flomoxef) concentration in body fluid. Chemotherapy 1987;35(suppl 1):129-136.
10. O'Callaghan CH, Morris A, Kirby SM, Shingler AH. Novel method for detection of β-lactamase by using a chromogenic cephalosporin substrate. Antimicrob Agents Chemother 1972;1:283-288.
11. Doem GV, Tubert TA. Detection of β-lactamase activity among clinical isolates of Branhamella catarrhalis with six different β-lactamase assay. J Clin Microbiol 1987;25:1380-1383.
12. Nakashima M, Katagiri K, Oguma T. Phase I studies on vancomycin hydrochloride for injection. Jpn J Chemother 1992;40:210-224.
13. Metzler CM, Elfring GL, McEwen AJ. A users manual for NONLIN and associated programs. The Upjohn Co, Kalamazoo, Mich.
14. Shimada K, Matsumoto T, Komiya I, Shinkai S. Phase I clinical studies on a novel oral cephem antibiotic, ME1207. Chemotherapy 1992;40(suppl 2):105-119.
15. Shimada K, Shishido A, Tsumoto M. Phase I study of cefdinir. Chemotherpy 1989;37(suppl 2):208-245.
16. Saito A. Pharmacokinetic studies on T-2588. Chemotherpy 1986;34(suppl 2):134-143.
17. Toothaker RD, Welling PD.The effect of food on drug bioavailability. Ann Rev Pharmacol Toxicol 1980;20:173-199.
18. Williams L, Davis JA, Lowenthal DT. The influence of food on the absorption and metabolism of drugs. Med Clin North Am 1993;77:815-829.
19. Muranushi N, Hashimoto N, Hirano K. Transport characteristics of S-1090, a new oral cephem, in rat intestinal brush-border membrane vesicles. Pharm Rev 1995;12:1488-1492.